Johnson and Johnson Delays Trial Due to Patient Ilness

Johnson and Johnson have a monitoring panel reviewing its trial for COVID-19 late stage vaccine trial. one of their patients in the study became ill with an unexplained illness.  after AstraZeneca Plc (AZN.L) Also delay trials of its Coronavirus  vaccine. the two companies used a similar technology to produce the vaccine. Currently, the information is being reviewed for a few days and that pauses are  a normal process  during large blind study clinical trials Involving thousands of patients  . Johnson and Johnson does not know if the person that felt ill was given a placebo or the vaccine.

This pause is not a regulatory hold that is imposed by health authorities.J&J says review of illness that led to pause of coronavirus vaccine trial could take days

Analyst Price Target on JNJ

$167.25

▲ (12.45% Upside)

Based on 8 analysts offering 12-month price targets for Johnson & Johnson in the last 3 months. The average price target is $167.25 with a high forecast of $175.00 and a low forecast of $158.00. The average price target represents a 12.45% increase from the last price of $148.73. Source TipRanks

Amazon’s new drone that films inside homes sparks controversy

When COVID-19 superspreaders are talking, where you sit in the room matters

Comments


CWEB.com is not registered as an investment adviser with the U.S. Securities and Exchange Commission. Rather, CWEB.com relies upon the “publisher’s exclusion” from the definition of investment adviser as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.

Full Disclaimer

%d bloggers like this: